Samska tolvaptan regulatory update

FDA's Cardiovascular and Renal Drugs Advisory Committee voted 8-3 to recommend approval of Samska tolvaptan for chronic oral treatment of hypervolemic or euvolemic hyponatremia. Otsuka is also seeking...